Terminated PHASE3 INTERVENTIONAL 2-arm NCT00257192

Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

Six Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Adolescent Subjects With Schizophrenia

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Conditions Schizophrenia

Interventions Ziprasidone oral capsules placebo

Updated 9 times since 2017 Last updated: Mar 2, 2021 Started: Apr 30, 2006 Primary completion: Mar 31, 2009 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Please see Detailed Description for termination reason.

Other terminated trials from Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

More terminations from Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Other Schizophrenia trials with similar outcome

Browse all Schizophrenia trials

Listed as NCT00257192, this PHASE3 trial focuses on Schizophrenia and remains terminated or withdrawn. Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc., it has been updated 9 times since 2006, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Apr 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 4 earlier versions

Jan 2021 — Apr 2021 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Apr 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Altamonte Springs, United States , Arlington, United States , Aurangabad, India , Aurora, United States , Birmingham, United States , Bogota, Colombia , Bothell, United States , Bridgeton, United States , Buffalo, United States and 62 more locations